News

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.
We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...
Verve Therapeutics licensed some of the base-editing technology VERVE-101 is based on from Beam Therapeutics. In October, Verve's collaboration partner, Eli Lilly, handed Beam $250 million upfront ...
Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.
Verve Therapeutics (NASDAQ: VERV) is up 16.5% for the week. The biotech stock, which was as low as $41.52 a share on Monday, climbed as high as $48.39 by Thursday. For a relatively new stock (it ...
Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human p ...
Since reporting some early-stage clinical data from one of its gene editing programs on Nov. 12, share prices of Verve Therapeutics (VERV-2.29%) are down 42%. But contrary to what you may be ...
Verve Therapeutics, Inc. (NASDAQ:VERV) is a Boston, Mass., based biotech that IPO'd in June 2021, raising ~$307m via the issuance of 16.1m shares priced at $19 per share.
Beam is selling Lilly the opt-in rights to a trio of candidates covered by an agreement it signed with Verve Therapeutics in 2019 for $200 million in upfront cash, ...
Why Verve Therapeutics stock tanked. There were no issues on the safety front that clearly indicate trouble ahead for VERVE-101 but the initial portion of the study was less than flawless.